UK says it won't purchase AstraZeneca's Covid treatment due to 'insufficient' Omicron data — reports
Weeks after evidence suggested current Omicron subvariants may be less susceptible to AstraZeneca’s prophylactic Covid-19 treatment Evusheld, the UK has reportedly decided against buying doses for now.
The UK’s Department of Health said it won’t procure Evusheld doses due to “insufficient data on the duration of protection offered by Evusheld in relation to the omicron variant,” according to the BMJ, a peer-reviewed trade journal published by the British Medical Association.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.